Table III.
Prognostic value of GLTSCR1 expression for the BCR-free survival proportional hazards model.
| BCR-free survival | ||
|---|---|---|
| Variable | HR (95% CI) | P-value |
| Univariate analysis | ||
| Age, ≥60 vs. <60 | 1.319 (0.773–2.250) | 0.310 |
| PSA level, >4 vs. ≤4 | 10.426 (5.309–20.474) | <0.001b |
| Gleason score, <7 vs. =7 vs. >7 | 3.175 (1.881–5.360) | <0.001b |
| Tumor invasion, T1 vs. T2-T4 | 3.416 (1.714–6.810) | <0.001b |
| Distant metastasis, M0 vs. M1 | 3.536 (0.488–25.641) | 0.212 |
| Lymph node metastasis, N0 vs. N1 | 1.879 (1.049–3.365) | 0.034 |
| GLTSCR1 expression, low vs. high | 2.279 (1.284–4.047) | 0.005b |
| Multivariate analysis | ||
| Age ≥60 vs. <60 | 1.026 (0.594–1.771) | 0.927 |
| PSA level, >4 vs. ≤4 | 6.093 (3.015–12.316) | <0.001b |
| Gleason score, <7 vs. =7 vs. >7 | 2.326 (1.343–4.028) | 0.003b |
| GLTSCR1 expression, low vs. high | 1.829 (1.002–3.339) | 0.049a |
a
P<0.05
b
P<0.01. GLTSCR1, Glioma Tumor Suppressor Candidate Region Gene 1; BCR, biochemical recurrence; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.